Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Progression</td><td align="left">Definition</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Stage 0 to I</td><td align="left">Albuminuria &gt;30 mg albumin/gCrea in combination with a 3-fold increase from baseline in albuminuria, confirmed within 2 weeks.</td></tr><tr><td align="left" rowspan="2">Stage I to II</td><td align="left">(i) Twofold increase from baseline albuminuria, confirmed within 2 weeks</td></tr><tr><td align="left">(ii) Albuminuria &gt;300 mg albumin/gCrea at a single assessment.</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Alport syndrome disease progression in this trial.

International Scholarly Research Notices

tab2

Table 2

Table 2: Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients 

Table 2 | Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients 